Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alphalogix LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled within 1 distinct art unit by 1 distinct examiner. EBBINGHAUS, BRIANA NOEL is the busiest examiner for the company, currently responsible for the 1 pending action. This focused prosecution profile indicates a single point of interaction with the patent office, requiring a targeted approach to this specific examiner's requirements.
The concentration of the portfolio into a single art unit suggests a very specific technical focus within the broader biotechnology field. Since EBBINGHAUS, BRIANA NOEL is the only examiner involved, their individual interpretation of the law will be the primary factor in the case's outcome. Practitioners can focus entirely on the 1 pending action, ensuring that the response is tailored to the specific nuances of the Biotechnology & Pharmaceuticals unit involved. This singular focus allows for a deep dive into the examiner's specific concerns without the distraction of a larger, more diverse portfolio. The administrative complexity is minimal, as there are no competing procedural styles to manage across different art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EBBINGHAUS, BRIANA NOEL | 1 | 59.7% | +63.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18899395 | METHODS OF TREATMENT UTILIZING CANINE-SPECIFIC THERAPEUTIC COMPOSITIONS | EBBINGHAUS, BRIANA NOEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18899395 | METHODS OF TREATMENT UTILIZING CANINE-SPECIFIC THERAPEUTIC COMPOSITIONS | EBBINGHAUS, BRIANA NOEL | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18899395 | METHODS OF TREATMENT UTILIZING CANINE-SPECIFIC THERAPEUTIC COMPOSITIONS | EBBINGHAUS, BRIANA NOEL | 1632 | §102§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlphalogix LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Briana Noel Ebbinghaus has the most, with 1 of Alphalogix LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
